Published online Jan 27, 2021. doi: 10.4254/wjh.v13.i1.144
Peer-review started: August 31, 2020
First decision: November 3, 2020
Revised: November 16, 2020
Accepted: November 28, 2020
Article in press: November 28, 2020
Published online: January 27, 2021
The oral nucleos(t)ide analogue, entecavir (ETV) was demonstrated to reduce the rate of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-associated liver cirrhosis. However, the reduction in HCC is different in various countries of the world.
The relationship between the reduction of HCC and HBV genotypes is interesting.
We surveyed the differences in the reduction of HCC development following ETV administration in many countries.
We surveyed the differences in the reduction of HCC development following long-term administration of ETV based on already published articles using PubMed (2004-2019).
The countries which showed the greatest reduction in HCC development following ETV administration were Spain, Canada, and most ineffective countries or regions were South Korea, China, Taiwan, and Hong Kong. With ETV administration, the incidence of HCC in genotype D regions was significantly lower than that in genotype C regions. The initial HBV-DNA levels in genotype C patients was almost the same as that in genotype D patients. No relationship was observed between the prevalence ratio of HBV and the incidence of HCC following ETV treatment.
The effectiveness of ETV in preventing HCC development in HBV-associated liver cirrhosis is genotype-dependent.
In countries with low effectiveness of ETV in the prevention of HCC development, frequent surveillance using imaging modalities will be necessary.